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Antimetabolites that affect nucleotide metabolism
are frontline chemotherapy agents in several cancers
and often successfully target one carbon meta-
bolism. However, the precise mechanisms and re-
sulting determinants of their therapeutic value are
unknown. We show that 5-fluorouracil (5-FU), a
commonly used antimetabolite therapeutic with
varying efficacy, induces specific alterations to
nucleotide metabolism by disrupting pyrimidine
homeostasis. An integrative metabolomics analysis
of the cellular response to 5-FU reveals intracellular
uracil accumulation, whereas deoxyuridine levels
exhibited increased flux into the extracellular space,
resulting in an induction of overflow metabolism.
Subsequent analysis from mice bearing colorectal
tumors treated with 5-FU show specific secretion of
metabolites in tumor-bearing mice into serum that
results from alterations in nucleotide flux and reduc-
tion in overflowmetabolism. Together, these findings
identify a determinant of an antimetabolite response
that may be exploited to more precisely define the
tumors that could respond to targeting cancer meta-
bolism.
INTRODUCTION
Antimetabolite chemotherapy is one of the most-successful
therapeutic strategies for the treatment of neoplastic disease
(Kaye, 1998). It is also highly toxic while exhibiting variable effi-
cacy. Thus, identifying the precise situations where it might be
effective as a medicine is a pressing biomedical need. One
commonly prescribed example is 5-fluorouracil (5-FU), which
remains a frontline chemotherapy for multiple advanced stage
cancers, notably colorectal cancer (CRC) (Longley et al., 2003).Cell
This is an open access article under the CC BY-NHowever, there lacks a comprehensive and mechanistic under-
standing of its effects on metabolism that could have prognostic
value clinically (Locasale, 2013). This agent and other antimetab-
olite compounds are thought to target metabolic enzymes
that are either involved in nucleotide metabolism or the folate
cycle—directly affecting nucleotide biosynthesis and indirectly
affecting other metabolic processes that are coupled to the
flux into the nucleotide pool and one carbon metabolism. There-
fore, we reasoned its direct effects on metabolism might encode
information that could lead to biomarker identification for cyto-
toxic response that would improve the precision of its indication.
If successful, this endeavor would bring precision medicine
to a set of agents that have historically been thought to lack
specificity.
Many of the current chemotherapies target a metabolic
network known as one carbon metabolism. The serine, glycine,
and one carbon (SGOC) metabolic network involving the folate
and methionine cycles integrates nutritional status from amino
acids, glucose, and vitamins and generates diverse outputs,
such as the biosynthesis of lipids, nucleotides, and proteins;
the maintenance of redox status; and the substrates for methyl-
ation reactions. Recently, multiple studies have found newfound
roles of genes in this pathway in tumorigenesis (Locasale, 2013;
Mehrmohamadi et al., 2014). Examples include the presence of
cancer-driving genes, such as PHGDH, whose product diverts
glucose metabolism into one carbon metabolism (Locasale
et al., 2011; Possemato et al., 2011). Furthermore, in an analysis
of uptake and excretion rates measured across population of
cancer cells, glycine uptake was found tomost strongly correlate
with cell proliferation (Jain et al., 2012). Serine has also been
found to be essential for cell proliferation (Labuschagne et al.,
2014; Maddocks et al., 2013, 2016), and SHMT2, which encodes
a mitochondrial serine hydroxymethyltransferase, was shown to
provide context-dependent susceptible liabilities for tumor
maintenance (Kim et al., 2015; Ye et al., 2014). Together, these
newfound roles for genes in this network in cancer provide
further rationale for targeting the pathway in cancer in a specific
manner.Reports 15, 2367–2376, June 14, 2016 ª 2016 The Author(s). 2367
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Incorporation of 5-Fluorouracil into the Pyrimidine Pathway
(A) Metabolic pathwaymap of pyrimidine pathway, focusing on uracil, 5-FU, and their derivatives, with C representing cytidine and its derivatives. Metabolites are
dihydrouracil, fluoro-dihydrouracil (F-dihydrouracil), uracil, 5-FU, uridine-monophosphate (UMP), fluoro-uridine-monophosphate (F-UMP), uridine-diphosphate
(UDP), fluoro-uridine-diphosphate (F-UDP), uridine-triphosphate (UTP), fluoro-uridine-triphosphate (F-UTP), deoxyuridine (dUridine), fluoro-deoxyuridine
(F-dUridine), deoxyuridine-monophosphate (dUMP), fluoro-deoxyuridine-monophosphate (F-dUMP), deoxyuridine-diphosphate (dUDP), fluoro-deoxyuridine-
diphosphate (F-dUDP), deoxyuridine-triphosphate (dUTP), fluoro-deoxyuridine-triphosphate (F-dUTP), thymine, thymidine, deoxy-thymidine-monophosphate
(dTMP), deoxy-thymine-diphosphate (dTDP), deoxy-thymine-triphosphate (dTTP), phosphoribosyl pyrophosphate (PRPP), methylene-tetrahydrofolate (meTHF),
and tetrahydrofolate (THF).
(B) Correlations of uptake and excretion rates of metabolites with IC50 of 5-FU response across NCI-60 cell line panel.
(C) IC50 data for five cell lines. Error bars represent ± SEM.In this study, we investigated how a commonly used cancer
chemotherapeutic 5-FU affects one carbon metabolism and a
key component of its function, nucleotide synthesis. We ques-
tioned whether there is any specific molecular mechanism that
defines its actions. Using a recently developed high-resolution
liquid-chromatography-mass-spectrometry-based technology
(Liu et al., 2014; Ser et al., 2015), simultaneous targeted profiling
of hundreds of metabolites is possible (Liu et al., 2014). This
approach is able to robustly quantify metabolites in concentra-
tion ranges over four orders of magnitude and has been previ-
ously applied to study the SGOC network (Mentch et al.,
2015). Metabolite profiling and flux profiling have offered valu-
able insights into metabolism and its role in pathophysiology
(Johnson et al., 2016; Zamboni et al., 2015). We therefore hy-2368 Cell Reports 15, 2367–2376, June 14, 2016pothesized that exploiting the use of this technology could iden-
tify unexplored mechanisms that mediate the action of 5-FU and
thus bring additional context to precisely define its indication.
RESULTS
Disruption of Pyrimidine Metabolism Defines the
Commonality of Response to 5-FU among Different
Cancer Cells
5-FU is an antimetabolite agent that targets nucleotide meta-
bolism and is metabolized as a mimetic of uracil (Figure 1A).
To first assess the molecular features that might determine its
efficacy, we examined the NCI-60 cell line compendium and
correlated the extent of cytotoxicity on each cell line as
measured by the inhibitory curve at 50% (IC50) value with the up-
take and excretion rates of a set of metabolites (Figure 1B). The
Spearman correlation analysis indicated that the IC50 value was
most positively correlated with 4-hydroxybenzoate, glycine, and
20-deoxycytidine but negatively correlated with homocysteine,
xanthosine monophosphate (XMP), oxidized glutathione, and
50-adenosyl homocysteine. These findings indicate that fluxes
related to SGOC metabolism associate with the response to
5-FU. They also suggest that 5-FU likely has effects on multiple
aspects of the SGOC network, including effects on metabolite
flow in one-carbon metabolism (glycine, homocysteine, and
50-adenosyl homocysteine), nucleotidemetabolism (20-deoxycy-
tidine and XMP), and in cellular redox (glutathione). Although the
correlation coefficient is small for each individual metabolite, the
overall trend in the rankings of the correlation indicates that
the SGOC network is related to 5-FU sensitivity, suggesting
that some predictive ability may be present in the secretory
fluxes of the SGOC network.
We extended these initial findings by carrying out a metabolo-
mics analysis of 5-FUon a panel of CRCcells. CRCcells (SW620,
SW480, HT29, HCT116, and NCI-H508) were chosen because
5-FU remains themost commonly prescribedagent for advanced
stage CRC. We first established the cytotoxic dose of these cell
lines (Figure 1C). Interestingly, the IC50 for each cell line was
highly consistent, exhibiting a range between 3 and 9 mM.
Next, we investigated the global intracellular metabolic
changes in CRC cells. The metabolite profile of a panel of CRC
cells was assessed 6 hr after treatment with 5-FU, a time point
that precedes a majority of the indirect effects of cytotoxicity
and cell-cycle processes, while allowing the metabolite effects
to be probed. We generated a profile of 339 metabolites and
an additional ten compounds that are fluorinated derivatives of
5-FU for the different cells near the IC50 dose. An unsupervised
hierarchical clustering revealed widespread heterogeneities in
metabolite levels across cell lines and in response to 5-FU
(Figure S1A; Table S1). Only a few metabolites showed common
features across the five CRC cell lines (Figure 2A). However, the
major differences in metabolite levels across the panel are
observed to be cell-type-specific differences rather than drug-
dependent changes, suggesting that metabolism does not
exhibit universal global perturbations with this treatment. An
examination of the redox and energy status, two measurements
of global metabolic changes, shows great variation between the
cell lines. Comparing the ratios for 5-FU treated to non-treated
cell lines, the NAD+-mediated redox status is decreased, with
increasing NADH/NAD+ ratios across all cell lines (Figure 2B).
In addition, decreasing glutathione (GSH)/glutathione disulfide
(GSSG) ratios, indicative of oxidative stress, were observed in
all cell lines except the HT29 cell line (Figure 2C). The ATP/
ADP ratio also decreased across all the cell lines, implying a
decrease in energy metabolism (Figure 2D). To explore this
further, we also examined two 5-FU-resistant cell lines, namely
MDA-MB-231 and SKOV3, with IC50 at 498 and 169 mM, respec-
tively. Both cell lines showed no reduction in either NADH/NAD+
ratio or ATP/ADP ratio, although they both displayed a de-
creased ratio of GSH/GSSG (Figure S1C). Taken together, these
findings indicate that 5-FU commonly alters global redox and
energy metabolism in sensitive cells.The changes in metabolites upon 5-FU treatment were dis-
played in a volcano plot for each cell line that showed the fold
change and the p value for each metabolite (Figure 2E). The
plot indicates order of magnitude changes in certain metabolite
concentrations, with up to 30- to 50-fold changes in relative
levels being observed. This analysis allowed us to identify
commonalities across cells lines (Figures 2F and S1B) that
included the accumulation of intracellular 5-FU, an increase
in deoxyuridine-monophosphate (dUMP), and surprisingly a
depletion of acyl-carnitine compounds. The accumulation of
reduced nucleotides, such as deoxyuridine and deoxycytidine-
monophosphate (dCMP), was common across cell lines as
well. Similarly, intracellular accumulation of 5-FU, deoxyuridine,
and dUMP were also found in the two resistant cell lines
(Figure S1D). Twenty-four metabolites were affected by 5-FU
treatment in two or more CRC cell lines. Pathway analysis of
these metabolites revealed that 5-FU showed greatest impact
on pyrimidine metabolism, followed by cysteine and methionine
metabolism, which is coupled to the folate pool and effects on
carnitine metabolism. Also affected were purine and vitamin B6
metabolic pathways (Figure 2G). Given the most commonly
altered nucleobase-related metabolites were uridinylated
compounds, these findings indicate that thymidylate synthase
(TS) is the mechanistic target of 5-FU, likely leading to a direct
effect on carnitine metabolism.
Accumulation of Uracil-Related Metabolites at
Increasing Doses of 5-FU
Having established the metabolic profile near the IC50 dose of
5-FU, we explored the intracellular metabolic profile at different
doses of 5-FU. An unsupervised hierarchical clustering revealed
that increasing concentrations of 5-FU had an observable effect
on a small number of metabolites, either by increasing or
decreasing the levels of correlated groups of metabolites (Fig-
ure 3A; Table S2). Pathway analysis of metabolites that showed
dose-dependent response to 5-FU highlighted in Figure 3A
revealed that 5-FU had the most-significant impact on
pyrimidine, purine, and vitamin B6 metabolism (Figure 3B).
Most metabolites did not exhibit any changes in their levels,
and a view of the volcano plot confirmed this observation (Fig-
ure 3C). An increasing number of metabolites altered at higher
concentrations of 5-FU, with a majority of metabolites remaining
fairly constant.
An inspection of the commonalities across doses revealed an
accumulation of UXP, dUXP nucleotides, and fluorinated deriva-
tives of nucleic acids at the cytotoxic doses of 5 mM and 100 mM
(Figure 3D), confirming again targeted inhibition of TS as a major
target of 5-FU. Only at higher doses (100 mM) was the propaga-
tion of fluorinated nucleotide metabolism observed beyond a
couple steps in the pathway, suggesting that the pro-drug activ-
ity of 5-FU that occurs by competing with nucleobases for DNA
and RNA metabolism is not occurring at the lethal doses of the
compound and not contributing to the cytotoxic mechanism of
action. In addition, at nanomolar doses, no metabolites were
significantly affected.
A direct comparison of metabolite levels in drug-treated cells
to non-treated cells revealed accumulation of uracil and its de-
rivative metabolites at the cytotoxic doses (Figure 3E). dUMPCell Reports 15, 2367–2376, June 14, 2016 2369
Figure 2. Commonalities and Heterogeneities in Response to 5-FU
(A) Heatmap of metabolites in five different cancer cell lines. Three hundred fifty-three metabolites were log2, quantile normalized before Pearson hierarchal
clustering. Top 25 metabolites exhibiting a common 5-FU pattern were used. See Table S1 for full list of metabolites and Figure S1 for the heatmap of all
metabolites.
(B) NADH/NAD ratio.
(C) GSH/GSSG ratio.
(D) ATP/ADP ratio.
(E) Volcano plot for metabolites across the five cell lines.
(F) Metabolites with common changes (fold change > 2 and p < 0.05) in two or more cell lines.
(G) Pathway analysis of metabolites in (F).
Error bars represent ± SEM.and deoxyuridine showed the greatest accumulation with
increasing doses of 5-FU. Notably, a slight increase of uridine
was observed only at 100 mM 5-FU. A similar pattern was
observed for the fluorinated derivatives of nucleic acids (Fig-
ure 3F), indicating that metabolite levels are increased only at
super-lethal doses of 5-FU and not at lower doses. A closer in-
spection of metabolite levels reveals that dUMP was increased
while deoxy-thymine-triphosphate (dTTP) was decreased at,
but not below, the cytotoxic dose of 5-FU (Figure 3G).
Levels of deoxyuridine-diphosphate (dUDP) were increased to
4.68-fold by 5 mM 5-FU and 8.95-fold by 100 mM 5-FU. On
the contrary, UDP levels were not significantly altered by
5-FU, although an increasing trend was observed at 100 mM
dose of 5-FU. These data suggest that TS is inhibited at lethal2370 Cell Reports 15, 2367–2376, June 14, 2016doses of 5-FU and is likely the initiating event leading to cyto-
toxicity. Apart from metabolites in the pyrimidine pathway,
metabolites involved in one-carbon metabolism were also
affected (Figure 3H). Homocysteine levels decreased slightly
at higher doses, whereas a general increasing trend was
observed for the other metabolites in the pathway as drug
dose increases. Notably, in the resistant cell lines treated with
5 mM 5-FU, we saw a commonly reduced dTTP in a less extent
in comparison with that in HCT116 cells but no significant
accumulation of dUDP or metabolites in one-carbon meta-
bolism (Figure S1D). Together, these findings indicate that
specific effects on nucleotide metabolism with concomitant
disruptions to other aspects of SGOC metabolism appear to
be the mode of action contributing to cytotoxicity by 5-FU.
Figure 3. Dose-Dependent Accumulation of Uracil- and 5-Fluorouracil-Derived Metabolites in Intracellular Metabolome
(A) Heatmap for metabolites in HCT116 cells at four doses of 5-FU (0 mM, 100 nM, 5 mM, and 100 mM). See Table S2 for list of metabolites.
(B) Pathway enriched in selected metabolites in (A), with false discovery rate <0.3.
(C) Volcano plot.
(D) Venn diagram of overlapping metabolites altered (fold change > 2 and p < 0.05) at different drug doses.
(E–H) Metabolite ratios (5-FU versus vehicle): (E) metabolites derived from uracil; (F) metabolites derived from 5-FU; (G) metabolites involved with TS and RnR;
and (H) metabolites in one-carbon metabolism. Error bars represent ± SEM.Increased Export of Uridine-Related Metabolites
Identifies an Overflow Mechanism that Characterizes
the 5-FU Response
Thus far, we have profiled metabolites in response to 5-FU treat-
ment in different settings. These findings have indicated that
there are specific changes in metabolism related to the point of
action in the SGOC network. We next tested whether these
changes resulted in the identification of specific metabolic
alterations that could have predicative capacity in determining
cytotoxicity to 5-FU. Accumulation of uracil and uracil-related
metabolites at the cytotoxic doses of 5-FU suggests that the
homeostasis of the pyrimidine pathway has been disrupted.
Recently, it has been proposed that bacterial cells export excess
amounts of uracil-relatedmetabolites andmodulate the extent of
this export to achieve pyrimidine homeostasis (Reaves et al.,
2013). This process is termed overflow metabolism. Given the
changes in intercellular metabolism related to pyrimidine biosyn-
thesis, we suspect that these changes might manifest to differ-ences in the secretion rates of nucleotide-related intermediates.
To investigate the effects of this disruption on export of metab-
olites, a flux analysis of secreted compounds was considered.
In response to 5-FU treatment, the levels of excreted uracil
from cells remained fairly constant (Figure 4A). 5-FU levels in
the media remained fairly constant throughout the treatment as
well, indicating that there is no evidence of limitation in 5-FU
over the time course (Figure 4B). Pyrimidine-related metabolites
accumulated over time, with changes in uridine and deoxyuri-
dine levels at the cytotoxic dose of 5-FU, indicating that export
of these metabolites is promoted by 5-FU treatment (Figures
4C and 4D). Apart from metabolites in the pyrimidine pathway,
the levels of other metabolites were also altered by 5-FU. Pyru-
vate and lactate showed decreased levels, when considering
higher doses (100 mM) of 5-FU (Figures 4E and 4F). Hypoxan-
thine showed increased levels when comparing between 5-FU
at all doses to the vehicle (Figure 4G). Additionally, methyl-oxo-
pentanoate showed increased levels whereas dihomo-linolenicCell Reports 15, 2367–2376, June 14, 2016 2371
Figure 4. Increase in Uridine and Deoxyuridine Levels in Extracellular Metabolome Suggests Directed Overflow Metabolism
(A–I) Relative quantities of excreted metabolites at 6 hr: (A) uracil; (B) 5-FU; (C) uridine; (D) deoxyuridine; (E) pyruvate; (F) lactate; (G) hypoxanthine;
(H) methyl-oxopentanoate; and (I) dihomo-linolenic acid.
(J) Diagram showing metabolites accumulating (arrow up) and decreasing (arrow down) in the extracellular space.
(K) Schematic diagram of overflow metabolism due to 5-FU inhibition.
Error bars represent ± SEM.acid showed increased levels when comparing between 5-FU at
all doses to the vehicle (Figures 4H and 4I). Interestingly, in resis-
tant cell lines, 5-FU (5 mM) caused no overflow of deoxyuridine,
and a significantly higher extracellular level of uridine was only
found in MDA-MB231 cells (Figure S2). No other common and
obvious changes among the other metabolites were observed
by 5-FU (Figure S2). Together, these findings point to a model
(Figure 4J) whereby a block in TS induces differential export of
metabolites proximal in the network to its disruption.
The effect of 5-FU onmetabolite excretion, taken together with
the intracellular metabolic response, suggests that overflow
metabolism is occurring in these mammalian cells and that
amount of flux directed into overflow metabolism is affected by
the extent of inhibition of TS (Figure 4K). In the presence of
5-FU, TS is inhibited, resulting in depletion of thymine levels
and an accumulation of uracil and uracil-derived metabolites.
This accumulation of metabolites is then attenuated by2372 Cell Reports 15, 2367–2376, June 14, 2016increasing export of uridine and deoxyuridine. Hence, overflow
metabolism of uridine and deoxyuridine is observed and modu-
lated by the targeting of enzymes involved in pyrimidine
metabolism.
Overflow Metabolism Observed in an In Vivo Tumor
Response to 5-FU Treatment
The observation of overflow metabolism in the pyrimidine syn-
thesis pathway and that it can be altered by targeting TS with
5-FU lends itself to intriguing possibilities for precision cancer
therapy. One possibility would be that, in vivo, the alteration in
overflow metabolism would propagate into circulation through
the tumor vasculature and result in a directed flow of metabolites
in pyrimidine metabolism into the serum. Thus, the relative levels
of pyrimidine metabolism intermediates that are present in the
serum would determine the extent of 5-FU response. To further
investigate the induction of overflow metabolism, non-obese
Figure 5. 5-FU Alters Overflow Metabolism In Vivo, and the End Products Can Be Measured in Serum
(A) Experimental design.
(B) H&E staining of colon tissue derived from HCT116-injected tumor-bearing mice treated with or without 5-FU. The scale bar represents 50 mm, which was
computed from 403 magnification of histology slide.
(C) Volcano plot of metabolites in normal mice and tumor-bearing mice treated with 5-FU versus mice without treatment.
(D) log2 ratio of metabolite levels in untreated (tumor) and treated (tumor +5-FU) tumor versus normal mouse serum. Error bars represent ± SEM.diabetic (NOD)/severe combined immunodeficiency (SCID) mice
were injected with HCT116 colorectal cancer cells intravenously
as previously described and tumors developed orthotopically
(Chen et al., 2012). Tumors were allowed to fully develop prior
to starting 5-FU treatment (Figure 5A). Tissue sections of mouse
colon, stained with H&E, indicate tumor establishment and reso-
lution of colorectal tumors following 5-FU treatment (Figure 5B).
Of the 273 metabolites detected in the serum, most showed
minimal changes when comparing the effects of 5-FU treatment
to no treatment in both normal and tumor-bearing mice (Fig-
ure 5C). Metabolites in tumor-bearing mice showed the largest
increases under 5-FU treatment, as compared to normal mice
also treated with 5-FU, suggesting that the effects of 5-FU occur
primarily in a tumor-autonomous manner. Consistent with
directed overflow metabolism, deoxyuridine was found to be
greater with log2 (fold change) of 1.998 (p value = 0.016;
Student’s t test) when comparing 5-FU-treated tumor-bearing
mice to untreated tumor-bearing mice. This change was notobserved in normal mice when comparing 5-FU treatment to
no treatment. Taurodeoxycholic acid, a bile acid generated
from the transsulfuration pathway that is related to one carbon
metabolism, was also seen in greater quantities when comparing
5-FU-treated to untreated tumor-bearing mice with log2 (fold
change) of 3.014 (p value = 0.011; Student’s t test). Thus, this
suggests that the response to 5-FU has specific effects on the
excretion of metabolites from tumors in mice.
Comparing the 5-FU treatment effect in tumor mice to normal
mice, 5-FU and 5-fluorouridine levels both increased (Figure 5D).
Levels of uracil and uridine in the serum were not significantly
altered by 5-FU in tumor-bearing mice, although a trend toward
a reduction was observed with log2 (fold change) of 0.614 and
0.637, respectively. Other metabolites that increased signifi-
cantly are deoxyuridine and taurodeoxycholic acid, indicating
that these increases are specific to tumor-bearing mice
undergoing 5-FU treatment. In particular, taurodeoxycholic
acid is made from taurine, whose precursor is cysteine andCell Reports 15, 2367–2376, June 14, 2016 2373
homocysteine. These increases are specific to tumor-bearing
mice undergoing 5-FU treatment. All together, these findings
provide evidence for directed overflow metabolism and its mod-
ulation by an antimetabolite agent in vivo and provide mecha-
nistic insights into potential metabolite biomarkers formonitoring
the 5-FU response.
DISCUSSION
These studies allowed us to draw several new conclusions
regarding the mechanism of 5-FU action that has been reported
to be complex and involve multiple modes of action (Longley
et al., 2003; Singh et al., 2015). Our findings appear consistent
with the primary mechanism of 5-FU at cytotoxic doses being
the disruption of TS activity (Mojardı´n et al., 2013; Parker and Sti-
vers, 2011). Accumulation of dUMP and decrease of dTTP at the
lower dose of 100 nM 5-FU demonstrates inhibition of TS, an
enzyme that links the de novo synthesis of thymidine nucleotides
to the folate pool (Edler et al., 2002; Etienne et al., 2004; Wash-
tien, 1984). In comparison, the accumulation of fluorinated
uridine-triphosphate (UTP) and fluorinated dUMP with subse-
quent defects in nucleotide biosynthesis and genome mainte-
nance occurred at higher concentrations of 5-FU (100 mM),
suggesting that thymidine depletion had a much-greater effect
than incorporation of fluorinated nucleotides into DNA. Disrup-
tion to the activity of other enzymes involved in the action of
5-FU, including ribonucleotide reductase (RnR) (Elford et al.,
1977; Fukushima et al., 2001), was not apparent.
In response to this disruption of TS activity, we found that 5-FU
induces a change to an overflow metabolism mechanism previ-
ously demonstrated only in bacterial cells (Reaves et al., 2013)
but, to our knowledge, hasnot been shown inmammals.Overflow
metabolism, a mechanism to maintain homeostasis in the pyrim-
idine pathway, results from the accumulation of uracil products
caused by limitations to the activity of TS as is observed upon
action of 5-FU. In cell culture, accumulation of uracil-derived me-
tabolites and an increase in their extracellular levels upon 5-FU
treatment provides direct evidence for this overflow metabolism
mechanism. In particular, we observed increased intracellular
and extracellular levels of deoxyuridine at higher concentrations
of 5-FU (5 mM and 100 mM). Whereas the intracellular level of
uridinewasonly increasedat 100mMof5-FU, its extracellular level
was elevated at all tested concentrations of 5-FU (100 nM, 5 mM,
and 100 mM). The lack of corresponding increase of intracellular
uridine at 100 nM and 5 mM of 5-FU could be due to increased
cellular export of uridine to maintain the cellular homeostasis of
uridine. These observations in vitro corroborate with our in vivo
study, where 5-FU altered nucleotide flux in tumor-bearing
mice, exhibiting changes in deoxyuridine excretion upon 5-FU
treatment in serum. It is possible that such a mechanism could
potentially be used to stratify patient responses to 5-FU. Support-
ing this possibility, studies have also shown that uridine supple-
mentation reduces toxicity of 5-FU (van Groeningen et al.,
1993), perhaps through reversal of the overflow metabolism.
The metabolite profiling also revealed insights into the effects
of 5-FU on other downstream metabolic pathways. In particular,
one-carbon metabolism is heavily involved in cancer cell meta-
bolism (Kim et al., 2015; Labuschagne et al., 2014; Maddocks2374 Cell Reports 15, 2367–2376, June 14, 2016et al., 2013) and might be involved in the cellular response to
5-FU (Locasale, 2013). Correlations with 5-FU cytotoxicity and
metabolite export rates show negative correlations of homocys-
teine and S-adenosyl homocysteine (SAH) levels, whereas our
intracellular metabolomics shows decrease in homocysteine
levels and an increase in SAH levels. The metabolite levels in
tumor-bearing mouse serum show a decrease in detected
one-carbon metabolites upon 5-FU treatment. Homocysteine
consistently shows up in our analysis and leads to the biosyn-
thesis of taurine and the production of taurodeoxycholic acid.
Taurodeoxycholic acid was found in greater quantities in mouse
serum when tumor-bearing mouse was treated with 5-FU. This
suggests a coupling between folate metabolism and the trans-
sulfuration pathway.
There have been numerous recent findings that have identified
molecular mechanisms that underscore the heterogeneity of
these pathways in cancer pathogenesis (Locasale, 2013).
Although the metabolite profile is diverse across different cell
lines, a common response of altering overflow metabolism ap-
pears to be a mechanism that is conserved across cells. It is
also manifested to in vivo situations in tumor-bearing animals,
where it occurred primarily in a tumor-autonomous manner
with increased nucleotide secretion. Thus, metabolic profiling
the overflow metabolism in patients could possibly yield bio-
markers and would provide mechanistic insights into monitoring
and stratifying the response of patients to 5-FU. Genetic markers
of 5-FU response have been documented (Edler et al., 2002;
Etienne et al., 2004), and likely, further analysis will require addi-
tional integration of metabolomics with genetics. Nevertheless,
our current metabolomics approach emphasizes reliably
measurable differences and alterations in themetabolic network.
In the future years, simplified cost-effective assays could be
developed to specifically quantify smaller panels of metabolites
needed to characterize specific metabolic mechanisms.
Although this idea is at an early translational stage, our current
study provides a mechanistic framework in evaluating therapeu-
tic responses to a conventional, commonly used antimetabolite
drug 5-FU, for its more precise use in cancer therapy.
EXPERIMENTAL PROCEDURES
Cell Culture
MDA-MB-231 and SKOV3 cell lines were gifts from Dr. Donald McDonnell and
Dr. Alexander Nikitin, respectively. All the other cell lines were gifts from
Dr. Lewis Cantley’s laboratory. All cells were grown in RPMI 1640 supple-
mented with 10% fetal bovine serum and 100,000 units/l penicillin and
100 mg/l streptomycin.
Cell Proliferation
Colorectal cancer cell lines (SW620, SW480, HT29, HCT116, and NCI-H508)
were seeded in 96-well plates at a density of 2,000–5,000 cells per well. After
overnight of incubation, media were replaced with full growth RPMI medium
containing 1% DMSO or 5-FU (Sigma) at concentrations (10 nM, 100 nM,
1 mM, 10 mM, 100 mM, and 1 mM) for an additional incubation for 48 hr. Cell
viability was determined by crystal violet staining. Further details are provided
in the Supplemental Information.
Metabolite Profiling
SW620, SW480, HT29, HCT116, NCI-H508, MDA-MB-231, and SKOV3
cells were seeded in 6-well plates at a density of 2–53 105 cells per well. After
overnight incubation, cells were washed with PBS and treated with RPMI
medium containing vehicle (1% DMSO) or the noted concentration of 5-FU
for 6 hr. Metabolite extraction was conducted as previously described (Liu
et al., 2014) and detailed in the Supplemental Information.
5-FU Treatment in Colorectal Cancer Xenografts
All animal studies were approved by the Institute for Animal Care and Use
Committee at Cornell University. Six- to eight-week-old NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ male mice were used for the study (cat. no. 005557; The Jack-
son Laboratory). 53 105HCT116 cells were injected in the tail vein. At 2 weeks,
5-FUwas introduced into the drinkingwater of tumor-bearingmice at a dose of
100mg/kg. At 4weeks, micewere sacrificed for tissue collection. Tissueswere
fixed in 4% paraformaldehyde for H&E staining. Serum was snap frozen for
metabolomics analysis.
Liquid Chromatography-Mass Spectrometry
Liquid chromatography (Ultimate 3000 Dionex) was coupled to a Q Exactive
Mass Spectrometer (Thermo Scientific). Detailed method and analysis are
provided in the Supplemental Information.
Statistical Methods
Data represent mean ± SEM unless otherwise noted. All hypothesis
testing was conducted with a two-tailed Student’s t test unless otherwise
noted. * denotes p < 0.05 unless otherwise noted.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.05.035.
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